Steven Robinette is a principal and focuses on the formation and operations of companies translating emerging biology into novel therapeutics. Steven was a member of the founding teams of Kymera Therapeutics (NASDAQ: KYMR), Disarm Therapeutics (acquired by Eli Lilly), Disc Medicine, Korro Bio, and Vigil Neuroscience. Additionally, he was involved in Atlas’ investments in Vedere Bio (acquired by Novartis), Arkuda Therapeutics, and Accent Therapeutics. Steven serves as an advisor to several organizations, including Brown Biomedical Innovations, Brandeis SPROUT, and Alexandria’s Seed Capital advisory board. Prior to joining Atlas Venture in 2015, Steven was an engagement manager at McKinsey & Company, serving pharmaceutical and biotechnology clients in the R&D service line.
Steven received his Ph.D. from Imperial College London, where he studied the biochemical genetics of rare disease in the laboratory of Jeremy Nicholson, and through a graduate partnership program with the laboratory of William Gahl at the National Human Genome Research Institute. Steven’s graduate work was sponsored by the British Marshall Scholarship, the NSF Graduate Research Fellowship Program, and the NIH Oxford-Cambridge Scholars Program. Steven received his B.S. in biochemistry and molecular biology from the University of Florida where he graduated summa cum laude, valedictorian and was a Barry Goldwater Scholar.
Outside of the office, Steven spends as much time as he can outdoors; hiking, skiing, sailing, and in his gardens and orchard. He and his wife and daughter live in Fremont, NH.